Jiangsu Hengrui Medicine Co.Ltd(600276) independent directors
On matters related to the 16th meeting of the 8th board of directors
separate opinion
In accordance with the company law, the securities law, the rules for independent directors of listed companies, the guidelines for corporate governance of listed companies, the Listing Rules of Shanghai Stock Exchange and other relevant laws and regulations, normative legal documents and the relevant provisions of Jiangsu Hengrui Medicine Co.Ltd(600276) articles of association, as independent directors of Jiangsu Hengrui Medicine Co.Ltd(600276) (hereinafter referred to as “the company”), based on independent judgment, We hereby express our independent opinions on the proposal on share repurchase plan of the company considered at the 16th meeting of the eighth board of directors as follows: 1 The shares repurchased by the company this time comply with the provisions of laws, regulations and normative documents such as the company law, the securities law, the rules for share repurchases of listed companies, the guidelines for self discipline supervision of listed companies of Shanghai Stock Exchange No. 7 – share repurchases. The convening, convening and voting procedures of the board of directors of the company comply with the provisions of relevant laws and regulations, normative documents and the articles of association.
2. The company’s share repurchase is conducive to improving the long-term incentive mechanism of the company’s employees, fully mobilizing the enthusiasm of employees, enhancing investors’ confidence in the company’s future development, enhancing investors’ recognition of the company’s value, and contributing to the sustainable development of the company.
3. This repurchase is implemented in the form of centralized bidding, and there is no situation that damages the interests of the company and all shareholders, especially minority shareholders.
4. The capital source of this share repurchase is the company’s own funds. This repurchase will not have a significant impact on the company’s operation, finance, R & D, capital status and future development. This share repurchase is reasonable and feasible, will not affect the company’s listing status, and will not damage the legitimate rights and interests of the company and shareholders.
In conclusion, we believe that the share repurchase complies with the provisions of relevant laws, regulations and normative documents, and the repurchase scheme is reasonable and feasible, which is in line with the interests of the company and all shareholders. Therefore, we agree that the company will implement this share repurchase.
Independent directors: Dong Jiahong, Wang Qian, Xue Shuang March 13, 2022
